DEA Developing Pain Drug Prescribing Policy
This article was originally published in The Pink Sheet Daily
Agency is soliciting comments for document intended to “reiterate legal concepts.” New principles will not be outlined, but DEA is hoping to create a “single, comprehensive document” after withdrawing a list of frequently asked questions because of “misstatements.”
You may also be interested in...
Sepracor plans for Lunesta to be available within the first quarter of 2005 after the completion of formal Drug Enforcement Agency classification of eszopiclone as a Schedule IV substance. The company originally planned to launch the insomnia agent in early January following FDA approval in December.
Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.